Alveolar and embryonal rhabdomyosarcoma (RMS) are soft-tissue cancers that affect children, adolescents, and young adults. Sometimes referred to as muscle cancer, RMS is a cancer of muscle and non-muscle origin that phenocopies incompletely differentiated myoblasts or activated satellite (muscle stem) cells.
Introduction
The long-term outcome for most children with progressive/metastatic rhabdomyosarcoma (RMS) has remained dismal for more than 4 decades 21 . While temsirolimus offers a short-term survival benefit 16 , new approaches for improved long term survival benefit are needed.
Studies by Shern, Khan et al. 22 have created interest in the RAS-MEK-ERK pathway for RMS. From 147 rhabdomyosarcoma samples investigated by whole genome sequencing or whole exome sequencing, 11
cases (11.7%) harbored NRAS mutations, 6 cases (6.4%) harbored KRAS mutations, and 4 cases (4.3%)
harbored HRAS mutations. Thus, 22% of cases for fusion negative tumors (ERMS) harbor RAS mutations 22 ;
however, fusion positive alveolar RMS (ARMS) in general do not.
RAS is upstream of MEK1/2 and in turn ERK1/2 8 . Cobimetinib is a representative MEK inhibitor. The literature does not yet systematically address the use of MEK inhibitors in RMS, but published studies are informative for the MEK1 signaling pathway as a target. In the ERMS cell line RD (harboring an NRAS Q61H mutation), the MEK inhibitor U0126 induced G1/S cell cycle arrest and reduced cell growth 8-fold 14 .
Synergy with irradiation is also observed 15 . For the same cell line, the MEK inhibitor AZD6244 slowed tumor growth with an IC50 of ~ 100 nM (by comparison, for the ARMS cell line Rh30, the IC50 for AZD6244
was > 10 uM 13 ). Soberingly, AZD6244 had no affect on tumor growth as a single agent in RD xenografts despite phospho-ERK reduction in peripheral mononuclear cells. Combining MEK and AKT inhibitors synergistically further slowed (but did not stop) tumor growth 19 . These results point to an interest in MEK inhibitors for RMS, but likely in the context of better drug combinations rather than as a single agent.
We address a unique therapeutic application of MEK inhibitors as agents that halt tumor growth by the induction of terminal myogenic differentiation. Clinical evidence suggests that inducing terminal differentiation of tumor cells is a feasible goal since myogenic differentiation under stress is an intrinsic property of RMS after treatment with chemotherapy and radiation 4, 9, 24 . This effect is more prominent in ). Nevertheless, fully harnessing embryonal and alveolar RMS differentiation potential clinically is the purpose of this study.
We have evaluated two differentiation-therapy strategies in this report. The first strategy hypothesizes that chemotherapy-induced myogenic differentiation in RMS is a 2-step process: (i) debulking the tumor cell mass with stress-inducing chemotherapy, then (ii) MEK inhibition-induced reprogramming of tumorpropagating cells (TPCs) into terminally-differentiation myogenic cells. The second strategy hypothesizes that preexposure of tumor cells to MEKi prior to chemotherapy treatment will sensitize RMS cells to chemotherapy-induced differentiation.
In our studies, we found that RMS cell lines exhibit a broad range of sensitivity to MEK inhibitors and chemotherapy agents. We also found that MEKi and chemotherapy agents can behave antagonistically in RMS; that is, treatment with a MEKi can decrease chemotherapy sensitivity. Finally, we found that MEKi and chemotherapy treatment induces myoblast differentiation but that this treatment strategy is insufficiently robust to support clinical development in RMS.
MEK1/2 pathway components are selectively over-expressed at the RNA level MEK1 is highly expressed in ERMS and in some ARMS biopsies. The MAPK signaling pathway components are highly expressed in selected ARMS cases as well ( Figure 1 ). As a secondary check to simple gene expression data, pathway signatures have been assessed using S-score method described previously 1, 20 . We have already shown that 21% of ERMS have a strong "RAS-on" signature 20 and upon examination 23% of fusion-positive ARMS have this same RAS-on signature (Figure 2A and 2B).
Interestingly, MEK1 or MEK2 expression were each associated with improved survival following chemotherapy in the Intergroup Rhabdomyosarcoma Study-IV (Suppl. Figure 1 ).
MEK1/2 pathway components are selectively over-expressed at the protein level
We performed immunohistochemistry of the MEK targets ERK1/2, scoring each sample by intensity and fraction (%) cells stained ( Figure 3 ). In brief, ERK1/2 phosphorylation is found in 36% of ERMS and 14%
of fusion-driven ARMS, in both nuclear and cytoplasmic patterns, and in both tumor cells and microenvironment cells (vascular endothelium/stroma) ( Figures 3A and 3B ). This result is consistent with our earlier finding that both ERMS and ARMS are associated with a RAS-on signature. Immunoblotting studies were also performed to discern tumor cell vs microenvironment phosphorylation status of this MEK1 target. We also evaluated fresh RMS biopsies for phosphorylated-ERK1/2 and similar to IHC, biopsies showed variable phospho-ERK expression ( Figure 3C ).
RAS signaling in RMS may generally be a modifier of disease rather than a driver
For the "RAS-on" signature in ERMS 20 , and in ARMS presented above, we posited that if RAS signaling were a driver event, then a RAS-on signature would exist exclusive of other RMS pathway signatures. uncommonly as a driver mutation. Thus, the p53-off state was the most common signature abnormality found either alone or in combination, while the other signatures (SHH activation, RAS activation, RB inactivation) were rarely found without a combined p53-off signature ( Figure 2 ). This results for a RAS activation signature as a modifier of disease, but not as a driver, is similar to what we had reported for sensitization, and MEKi-induced antagonism of chemotherapy. We note that these three types of response were independent of RMS pathology (ERMS or ARMS), and independent of chemotherapy tested. We attempted to determine a molecular marker that would correlate with the three types of response. For this, we surveyed representative cell lines for their phospho-ERK1/2 status. All cell lines evaluated have similar levels of phospho-ERK1/2 prior to drug treatment, except for Rh30, which was lower. ( Figure 5C ).
Response of MEKi-alone and combination MEKi plus chemotherapy treatment of RMS cell lines in a differentiation assay
We further evaluated MEKi (cobimetinib) and chemotherapy (vincristine) treatment in a myogenic differentiation assay ( Figure 6 and Supple. MEK inhibitors in general, and cobimetinib specifically, have been reported to work through G1 phase cell cycle arrest in several cancer types 7, 17, 26 . In contrast, chemotherapy agent vincristine is an inhibitor of microtube formation that primarily impacts chromosome separation during metaphase. Rather than working synergistically to induce differentiation as originally envisioned, our data could be interpreted as consistent with cobimetinib and vincristine mechanistically working as cell cycle inhibitors. That is, for some RMS cell lines pretreatment with cobimetinib induced G1-arrest that then reduced the effectiveness of vincristine that works later in the cell cycle. Nevertheless, neither mafosfamide (cyclophosphamide) or vinorelbine were synergistic with cobimetinib either.
Materials and methods

Cell Lines
Cell 
Western blot analysis
For western blot analysis, protein lysates were prepared using a standard RIPA buffer (Thermo Cat# 89900) and cell scrapping method. The RIPA buffer was supplemented with HALT protease and phosphatase inhibitor cocktail (Thermo Cat# 78441). Protein lysates were sampled for bicinchoninic acid assay (BCA) 
Sequence analysis
DNA and RNA sequencing methodologies were previously published (Nat. Med. 2015 June; 21 (6): 555-559). Data were obtained from the OncoGenomic DB maintained by the laboratory of co-author Javed Khan (National Cancer Institute).
Microarray analysis for S-Scores and Principal Component Analysis
Human microarray datasets were previously published 6, 10, 30 . Patient demographics are presented in Supplemental Tables 1a and 1b . Metagene and S-score analysis were conducted as previously described 20 .
For mouse tumors, gene expression analysis was performed using Illumina's Mouse Ref 8 Beadchip v1
(Illumina Inc, San Diego, CA). These datasets have been deposited in GEO as accession entry GSE22520
and described in Supplemental Table 1c . Rank invariant normalization was performed on the log2- as well as ARMS rhabdomyosarcoma datasets from previously published reports 10, 30 . These fusion negative RMS and ARMS datasets were designated as the test samples, whereas normal skeletal muscles (SKM) samples reported by Bakay et al. 3 were used as the control group. We also downloaded signature specific datasets as described in the paragraphs below. All the studies had been performed on Affymetrix U133A array platform (Affymetrix, Santa Clara, CA). Sample IDs used are given in Supplemental Tables   1 and 2 . Control samples of each examination are the embryonal rhabdomyosarcoma (ERMS) samples derived from Rubin et al. 20 . We have selected 10 high positive, 10 low positive and 10 negative control samples for each examination, whereas gene-wise t-tests were performed between the 20 positive controls and normal SKM in order to apply to S-score. S-score is a subtype scoring method to quantify each sample's consistency. By using the S-score, we can unambiguously identify sample status and the amplitude of pathways or biological processes that gene signatures have depicted. The detailed S-score method has been previously described 20 .
We used previously established gene lists 20 to examine whether human fusion negative RMS and ARMS tumors had evidence of p53 loss of function, SHH gain of function, RB loss of function, or RAS activation.
Gene signatures of p53 loss of function were derived from gene expression dataset in breast cancer 18 . We also downloaded datasets for medulloblastoma samples known to exhibit a SHH gain of function signature 29
. We took homolog genes from Rb1 wildtype and homozygous Rb1 deleted fusion-negative mouse sarcomas to be RB loss of function gene signature 20 . For Ras activation, we used gene lists for the activated RAS signature of zebrafish ERMS 11 . The details of obtaining gene signature of each case have been previously described 20 .
Tissue microarray analysis
Tissue microarray analysis was performed on 2 mm tissue punches that were formalin-fixed and paraffinembedded. The specimens were histological evaluated for rhabdomyosarcoma sub-type. Specimens were probed with phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (20G11) antibody (Cell Signaling Cat# 4376).
Cellular proliferation assay
MEK inhibitor (MEKi) and chemotherapy reagents were evaluated in a cellular proliferation assay. Both drugs were formulated to 10mM in DMSO. Rhabdomyosarcoma cell lines were seeded in 384-well plates at 2,500 cells per well, in 50 µL of media, using a Thermo Scientific™ Matrix Wellmate™ dispenser using a 10 µL tubing cassette. Two drug dosing schedules were evaluated in this study. In schedule 1, the day after cell seeding, cells were treated with MEKi at six concentrations of a log-based dilution series (0, 2.6 nM, 36 nM, 0.39 µM, 4.4 µM, and 50 µM). Drug was administered with a Tecan (Mannedorf, Switzerland)
D300e drug printer using a T8+ Dispensehead cassette. Following 24-hour MEKi treatment, chemotherapy drug was administered using the same protocol to generate a complete matrix of MEKi/Chemotherapy therapy. Cultures were then incubated for an additional 72 hours using standard conditions. For drug schedule 2, the day after cell seeding, the plates were treated with chemotherapy. After 48 hours of culturing the plates were then treated with MEKi. After 72 hours of complete drug treatment, cultures were treated with an equal volume of CellTiter-Glo© reagent (Promega Cat# 2020-01-29, Madison, WI). Plates were incubated for 10 minutes at room temperature, rocking while light-shielded. After which, luminescence was measured in a Biotek (Shoreline, WA) plate reader. The data was then analyzed using Prism (San Diego, CA) Graphpad© software.
Myotube differentiation assay
Cobimetinib (cobi) and vincristine (vcr) co-treatment was evaluated in a differentiation assay. Cell lines RD (Embryonic RMS) and Rh30 (Alveolar RMS) were seeded in 96-well plate at 5,000 cells per well. hr, hours; cobi, cobimetinib; vcr, vincristine; kD, kDal. Suppl. Figure 3 . Representative images of IHC staining used to calculate graphs in Figure 6 . Blue, 
